“showed a trend”

Patients with UC showed a trend to an increased ARFID risk, without reaching significant differences with CD (62.5% UC vs 37.5% CD; P = .07).

In patients with non-Class I mutations, tobacco users treated with ICI-based therapies (n=36) showed a trend towards improved PFS (14.2 vs. 7.5 months; p = 0.07) and OS (18.8 vs. 9.7 months; p = 0.07) compared to never-smokers (n=6).

Patients with PiCCO-monitoring showed a trend to higher SOFA-values compared to the patients without PiCCO (11.45 vs. 9.76; p=0.070).

Depression and belongingness showed a trend (depression: β=−0.28, t (485)=−1.85, P =0.07; d=0.10; belongingness: β=0.56, t (506)=1.72, P =0.09; d=0.06).

The APN intervention significantly reduced adjusted systolic BP in the experimental group compared with the “usual care” group (−2.72 mm Hg, p = 0.04) and showed a trend toward a decrease in adjusted diastolic BP (−1.85 mm Hg, p = 0.07) and improved BP control with the APN intervention (−8.5%, p = 0.08).

Patients in risk group 5 (M1 disease or PSA > 100 μg/l) showed a trend toward higher pro-NPY levels compared with all other risk groups combined (median 0.145 vs. 0.0965 ng/ml, p = 0.070) (Fig. 1 B).

Older age showed a trend toward increased non-adherence ( p = 0.07), while gender, subspecialty, fellowship status, workplace, and procedure volume were not associated with prescribing practices.

Women showed a trend toward more moderate‐to‐severe bleeding (4.6% versus 2.8%; adjusted HR, 1.63 [95% CI, 0.96–2.72]; P =0.070).

Long-term guselkumab use showed a trend toward reduced relapse risk (HR 0.55, 95% CI 0.28–1.06, p = 0.07), whereas no significant difference was observed for secukinumab.

Moreover, the authors added that SLL in patients correlated significantly with WG ( P < .001) and showed a trend for an association with BMI gains ( P < .07).

Western blotting analysis of phospholamban (encoded by Pln ) phosphorylation showed a trend for increased phosphorylation in hearts from 3-month-old C. mdx 62 mice ( P= 0.07; Fig.

Subsyndromal PTSD subjects showed a trend for significantly higher heart-rate reactivity in comparison to non-PTSD participants ( p =.07), but not healthy controls ( p =.13).

Treatment with HSP60 peptide 180-188 alone showed a trend towards reduction of arthritis, without achievement of statistically significant differences (Day 23 p = 0.07, AUC p = 0.26 vs. no treatment).

In LOCAT, PPARA IVS7 2498 (designated “PPARA intron 7 G/C polymorphism” in the publication) C allele carriers had a significantly greater progression of coronary atherosclerosis compared with GG homozygotes [ 50 ]. No pharmacogenetic interaction was noted [ 50 ]. When the association of PPARA IVS7 2498 polymorphism with coronary atherosclerosis was investigated in 3,012 healthy middle-aged men in NPHS2, PPARA IVS7 2498 CC homozygotes showed a trend toward greater incidence of ischemic events (myocardial infarction (MI) or coronary revascularization) (HR 1.83; 95% CI 0.96–3.51; P = .07) compared to PPARA IVS7 2498 CG heterozygotes and PPARA IVS7 2498 GG homozygotes [ 50 ]. 2.4.2.

Spearman correlation showed a trend between word reading test speed and scholastic TMA ( p = 0.07) in the experimental group ( Figure 1 ).

Nutrition-related behavioral measures An eating disorder diagnosis based on the eating disorder questionnaire at age 20 showed a trend for higher prevalence in those with AIS compared with those without (25.0% vs 11.1%; p = .07), but this trend was not seen at younger ages ( Table 3 ).

16 In our study, the subgroup of patients with an initial FEV 1 35% to 65% of predicted showed a trend to benefit from augmentation therapy ( P = 0.07).

Q-PCR results showed a trend toward reduced viral burden in blood of mice treated with aIL-10r mAb prior to intraperitoneal WNV infection ( Figure 3 A , p = 0.07).

17 , 41 , 45 , 46 In the present study, ASD patients showed a trend‐level amplitude decrease in the P300 component ( p = 0.07).

Concomitant use of cyclophosphamide significantly increased the risk of cardiac dysfunction ( P = 0.048), while low BMI (<20 kg/m 2 ) and preexisting cardiac disease showed a trend towards increased risk of cardiac dysfunction ( P = 0.07 for both).

IL-7 levels showed a trend to be predictive for progressive and end-stage diseases compared with constant controls ( P = 0.07 and P = 0.09, respectively).

Analysis of fasting C-peptide within each group as a function of time showed a trend toward an increase in function ( P = 0.07) over the first posttransplant month only in the animals that received intraportal islet/MSC.

CRLB of metabolites that were significantly different or showed a trend between the two groups are marked with *p<0.07, **p<0.001.

The test for subgroup differences showed a trend toward statistical significance ( p = 0.07), thus no strong evidence of differential effects based on the method used to define sarcopenia was observed ( Supplementary File S6 ). - Overall survival (multivariate analyses, aHR): In the subgroup analysis for OS based on multivariate regression analyses’ reported outcomes, the pooled aHR for the 29 studies defining sarcopenia using SMI was 1.59 (1.40; 1.80), with substantial heterogeneity (I 2 = 79%, τ 2 = 0.06, p < 0.01).

Both groups had comparable duration of ICU stay, but patients in the loading group showed a trend towards longer overall hospital stay (14.0 vs. 11.1 days, p = 0.07).